The bifunctional chelator and radiometal have been shown to have a direct effect on the pharmacokinetics of somatostatin receptor (SSTR)-targeted imaging agents. We evaluated three Y3-TATE analogues conjugated to NOTA-based chelators for radiolabeling with 
S
OMATOSTATIN RECEPTORS are overexpressed on a variety of human neuroendocrine tumors and have become an important target for molecular imaging. There are five receptor subtypes; somatostatin receptor subtype 2 (SSTR2) is found in a variety of malignancies and has become the target for molecular imaging radiolabeled somatostatin analogues. [1] [2] [3] [4] [5] [6] [7] [8] [9] Previous research has demonstrated that somatostatin analogues can be labeled directly with 18 F and 124 I or modified with bifunctional chelators, allowing the incorporation of radiometals. [10] [11] [12] The radiometals 64 accumulation within the target site and clearance from nontargeted tissues and is also a promising radiometal for radiotherapy due to b 2 emission. 13 Gallium-68 (T 1/2 5 67.7 minutes; b + [87.7%] 1,899 keV) has become a more widely used radiometal for PET imaging due to the convenience of its production from a 68 Ge/ 68 Ga generator. 14 In addition, the high-energy positron emitted by 68 Ga has potential for Cerenkov luminescence imaging, which can be monitored using simpler and less expensive whole-animal optical imaging equipment.
Gaeluate was collected by desorbing it with 0.8 mL of 0.01 M HCl/98% acetone solution. HCT116 cells were provided by Dr. Bert Vogelstein at Johns Hopkins University and were transfected with SStr2 as previously described. 29 S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) was purchased from Macrocyclics (Dallas, TX), and 2,29-(7-(1-carboxy-4-((2,5-dioxopyrrolidin-1-yl)oxy)-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic acid (NODAGA-NHS ester) was purchased from CheMatech (Dijon, France). All other chemicals were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO) or Fisher Scientific (Pittsburgh, PA).
Synthesis of Y3-TATE Analogues
4,11-Bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane (CB-TE2A) conjugated to Y3-TATE was synthesized as previously reported. 29 The general protocol for peptide synthesis of the conjugates used for this study has been previously described. 28, 30 Briefly, the peptides were prepared on a solid support by standard Fmoc procedures using a preloaded Fmoc-Thr(Boc)-Wang resin. Fmoc deprotection was achieved by washing the resin with 20% piperidine DMF (five times) for 2 minutes, followed by washing the resin three times with DMF. The carboxyl group was activated using 2-(1H-benzotriazole-1-yl)-1,1,1,3-tetramethyluronium hexafluorophosphate (HBTU) and di-isopropylethylamine (DIPEA) to couple the subsequent Fmocprotected amino acids. Cyclization of the peptide was accomplished by treating the resin with Tl(TFA) 3 in dimethylformamide (DMF). Following cyclization, the Fmoc was removed from D-Phe to expose the free amine. The free amine was treated under three conditions to provide the Y3-TATE analogues for this study. NODAGA-Y3-TATE was prepared by treating the resin with NODAGA-NHS (2 Eq) and N,N9-diisopropylethylamine (DIPEA) (5 Eq) in DMF overnight. NOTA-PEG 8 -Y3-TATE (NOTA-PEG 8 ) was prepared by first treating the resin with Fmoc-PEG 8 -CH 2 CH 2 -COOH following standard Fmoc procedures. Following the deprotection, the resulting free amine was treated with p-SCN-Bn-NOTA (1.5 Eq) and DIPEA (6 Eq) dissolved in DMF and reacted overnight. NOTA-b-Ala-Y3-TATE (NOTA-b-Ala) was prepared under the same methods as NOTA-PEG 8 , with Fmoc-b-Ala used as the linker instead of Fmoc-PEG 8 -CH 2 CH 2 -COOH. The resins were washed, the individual peptides were cleaved, and side chain-protecting groups were removed using a trifluoroacetic acid (TFA) solution (90% TFA, 5% water, 5% triisopropylsilane). The cleaved peptides were precipitated out of solution using ice-cold diethyl ether and washed twice with diethyl ether. The peptides were dissolved in 10% acetic acid and purified using preparatory highperformance liquid chromatography (HPLC), where solvent A is 0.1% TFA in water and solvent B is 0.1% TFA in acetonitrile. The HPLC purification was carried out on a Phenomenex Jupiter 5u C18 300 Å semipreparative column (250 3 10 mm, 5 microns) starting at 82% A held for 2 minutes, then a linear gradient to 65% A over 10 minutes, followed by a linear gradient to 50% over 3 minutes and a linear gradient to 10% A over 1 minute. This was held for an additional minute followed by a linear gradient to 82% A over 1 minute and held for 4 minutes. The solvent was removed in vacuo to yield pure Y3-TATE analogues. The Y3-TATE analogues ( Figure 1) 
Synthesis of Cold Standards of Cu-and Ga-Y3-TATE Analogues
Cold copper labeling was achieved by reacting 300 mg of each of the NOTA-Y3-TATE analogues, 300 mL 10% acetic acid, and 2 mg of copper acetate for 30 minutes at 95uC. Cold gallium labeling was achieved under the same conditions using gallium trichloride. The reaction solution was purified using preparatory HPLC, where solvent A is 0.1% TFA in water and solvent B is 0.1% TFA in acetonitrile. The HPLC purification was carried out on a Phenomenex Jupiter 5u C18 300 Å semipreparative column (250 3 10 mm, 5 microns) starting at 97% A, a linear gradient to 3% A over 10 minutes, and then held for an additional 7 minutes. This was followed by a linear gradient to 97% over 1 minute and held for an additional 4 minutes. The desired peak was collected and solvent was removed in vacuo to yield pure Cu-and Ga-NOTA-Y3-TATE analogues. The Cu-and Ga-NOTA-Y3-TATE analogues were characterized on a Waters (Milford, MA) e2695/LCT Premier XE LCMS: Cu-NODAGA-Y3-TATE (C 64 H 87 CuN 13 Cu-CB-TE2A-Y3-TATE was prepared as previously described. 28 Quality control of the radiolabeled peptides was performed on a Waters 2489/1525 HPLC to determine radiolabeling yield.
Receptor Binding Assays
Membrane preparations of HCT116-SSTr2 cells were used for binding assays, and assays were performed on PerkinElmer Unifilter (Waltham, MA) 96-well, GF/B filtration plates using previously described methods, with some modifications. 28 Cu-NODAGA-Y3-TATE; data not shown). The cells were then washed twice with phosphate-buffered saline, OptiPhase Super-Mix (50 mL; PerkinElmer) was added to each well, and bound activity was measured with a liquid scintillation and luminescence counter (2450 Microbeta   2 ). The IC 50 values were calculated by fitting the quadruplicate data with nonlinear regression using GraphPad Prism software. The Ki values were calculated by using the Cheng-Prusoff equation. 32 
Internalization Studies
Internalization studies were performed as previously described. 27 Briefly, HCT116-SSTr2 cells were cultured in McCoy's 5A medium supplemented with 10% fetal bovine serum, 1% pencillin-streptomycin-glutamine, and Zeocin (1 mg/mL); cells were incubated at 37uC in a humidified 5% CO 2 atmosphere. Before each assay, aliquots of prepared 2 3 10 7 cells/mL were placed in a 12-well plate and incubated overnight. The wells were prepared as previously described, 27 and 64 Cu-labeled Y3-TATE analogues (6 ng/10 mL) were added to blocked and unblocked wells (n 5 3). Blocked wells were pretreated with 2 mg/10 mL of Y3-TATE and washed, and new growth medium was added. The cells were allowed to incubate for 10 minutes at 37uC. Following incubation, the medium was collected in separate fractions; the surface bound and the lysed cells were counted on a Packard Cobra II automated gamma counter (Packard Instrument Company, Downers Grove, IL). The total protein concentration in the cell lysate was determined using the BCA Protein Assay (Pierce Biotechnology, Rockford, IL). Internalized and surface-bound fractions were expressed as fmol/mg of protein.
Biodistribution
All animal studies were conducted under protocols approved by the University of Pittsburgh and Washington University Institutional Animal Care and Use Committees (IACUC). Biodistribution experiments were conducted as previously described with some modifications. 31 Briefly, healthy NCr nude female mice (6-8 weeks, Taconic Labs, Hudson, NY) bearing HCT116-SSTR2-positive tumors were injected with 64 Cu-and 68 Ga-Y3-TATE analogues (0.74-1.85 MBq) via the tail vein. Animals were sacrificed at selected time points following the injection, and organs of interest were removed, weighed, and counted on a WIZARD 2 gamma counter (PerkinElmer). In addition, blocking studies were performed for 64 Cu analogues at 4 hours where the mice were injected with 50 mg of Y3-TATE 30 minutes prior to injection of the radiotracer, except CB-TE2A-Y3-TATE, which was coinjected with 100 mg of Y3-TATE at 4 hours. The percent injected dose per gram (%ID/g) was calculated by comparison to a weighed, diluted standard.
PET/CT Imaging
Imaging studies were performed using NCr nude female mice (6-8 weeks, Taconic Cu-CB-TE2A-Y3-TATE was imaged as previously described at 2 hours postinjection. 27, 33, 34 All PET images were manually coregistered to the CT, analyzed, and prepared using the Inveon Research Workplace software (Siemens Molecular Imaging). PET images were exported as maximum intensity projections, and final images were prepared using ImageJ software (National Institutes of Health [NIH], Bethesda, MD) and Adobe Photoshop CS5.
Cerenkov Luminescence Imaging
Following PET/CT imaging, mice injected with 68 Ga-based probes were placed into an IVIS Lumina XR optical imaging station (PerkinElmer) to evaluate Cerenkov luminescence in the tumors. Images were acquired using the following parameters: no light acquisition filter, acquisition time: 300 seconds, binning: 8 3 8, F/stop: 1, field of view: 10 cm 3 10 cm. Animals were anesthetized with 2% isoflurane under oxygen with a flow rate of 2 L/min throughout imaging and were heated by a 37uC platform throughout imaging. Machine control was performed using Living Image software version 3.1 (PerkinElmer). The 16-bit TIFF output images were opened using ImageJ software, and outlier hotspots due to cosmic radiation were removed using the ''remove outliers'' tool. Images were then background subtracted using the rolling ball algorithm (radius 5 500 pixels). Free-hand regions of interest (ROI) were drawn around the tumor and the leg opposite the tumor as a muscle reference, and mean pixel intensities were measured within each ROI. Tumor to muscle ratios were then calculated. Image labels were added using Adobe Photoshop CS5.
Statistical Analysis
Prism version 5 software was used to determine p values and statistical significance. An unpaired t-test was used to compare biodistribution values presented in this article.
Results

Synthesis and Radiolabeling
Y3-TATE was prepared on resin as previously described. 28, 30 The terminal D-Phe was deprotected on the resin to expose the free amine for incorporation of the NOTA chelators and linkers. The free amine was modified to provide the chelator-Y3-TATE analogues in the following yields: NODAGA-Y3-TATE (1.9%), NOTA-b-Ala-Y3-TATE (2.1%), and NOTA-PEG 8 -Y3-TATE (3.4%). These analogues were radiolabeled in high yield and purity with 64 Cu ($ 95%) and 68 Ga ($ 99%). The specific activities ranged between 42.2 and 150.6 MBq/mmol (Table 1) .
Receptor Binding Assays
A saturation binding assay was performed using HCT116-SSTR2 membranes. 31 The dissociation constant (K d ) for 64 Cu-NODAGA-Y3-TATE (0.5 6 0.1 nM) was similar to the previously reported values for 64 Cu-CB-TE2A-Y3-TATE (Table 2) 29 ; however, the B max was greater for the CB-TE2A analogue compared to the NODAGA analogue (4200 6 
Competitive Binding Assays
The IC 50 values were determined in a competitive binding assay using 64 Cu-NODAGA-Y3-TATE as the radioligand and HCT116-SSTR2 membranes (see Table 2 ). The competitive binding assays were performed once, and the Ki value was calculated from the IC 50 using the ChengPrusoff equation. Cu-and Ga-NODAGA-Y3-TATE presented the lowest K i values for the NOTA analogues; both analogues had a K i of 0.6 nM. As seen with the dissociation constants, the addition of linkers demonstrated an increase in the K i values. For the b-Ala linker, the cold Cu analogue had a K i of 1.5 nM, which was slightly lower than the Ga analogue, with a K i of 4.0 nM. The difference between the Cu-and Ga-NOTA analogues was the greatest for NOTA-PEG 8 -Y3-TATE: Cu-NOTA-PEG 8 -Y3-TATE (K i 5 16 nM) and Ga-NOTA-PEG 8 -Y3-TATE (K i 5 2.5 nM).
Internalization Studies
Internalization studies were performed with HCT116-SSTR2 cells (Figure 2 ). Cu-CB-TE2A-Y3-TATE demonstrated significantly higher uptake in the tumor (15 6 4.8% and 13 6 3.1 %ID/g) than both the PEG 8 and b-Ala analogues (5.5 6 1.7 and 5.8 6 2.6 %ID/g; p , .01). At 24 hours, 64 Cu-NOTA-PEG 8 -Y3-TATE (5.2 6 1.2 %ID/g; p , .03) presented with the highest tumor uptake, but uptake in the kidneys and liver was greater than in the CB-TE2A, NODAGA, and b-Ala analogues. Cu-CB-TE2A-Y3-TATE at 24 hours had the highest tumor uptake (3.3 6 0.5 %ID/g; 3.3 6 0.3 %ID/g), Cu-NOTA-b-Ala-Y3-TATE showed the highest uptake in the kidneys (3.0 6 0.3 %ID/g), followed by the tumor (1.1 6 0.3 %ID/g).
Of all compounds evaluated, 64 Cu-NODAGA-Y3-TATE demonstrated superior tumor to blood/muscle ratios for all time points; however, at 1 hour, the tumor to blood/muscle ratio of 64 Cu-NODAGA-Y3-TATE and the tumor to muscle ratios of all the 64 Cu-labeled NOTA analogues at 4 hours were not statistically significant (p $ .07) compared to 64 Cu-CB-TE2A-Y3-TATE (Table 3) . For the NOTA analogues, 68 Ga-and 64 Cu-labeled NODAGA-Y3-TATE provided the highest tumor to blood/muscle ratios. The tumor to muscle and tumor to blood ratios for the 64 Cu-labeled analogues were highest at 4 hours with the exception of NOTA-PEG 8 -Y3-TATE, where the tumor to muscle/blood ratios were similar at 1 and 4 hours (see Table 3 ). 64 Cu-CB-TE2A-Y3-TATE demonstrated the highest tumor to muscle/blood ratios of all the analogues at 1 hour (74 6 25 and 120 6 60, respectively). Of the NOTA analogues at 1 hour, 64 Cu-NODAGA-Y3-TATE demonstrated the highest tumor to muscle/blood (73 6 78 and 58 6 26, respectively); however, it should be noted that the differences in tumor to muscle ratios are not statistically significant.
Blocking with unlabeled Y3-TATE demonstrated a reduction in SSTR2-targeted agents for all compounds. Preblocking caused a 90% decrease in tumor uptake of Cu-CB-TE2A-Y3-TATE (6.1 6 1.6 %ID/g) was coinjected with Y3-TATE but still demonstrated reduced uptake in the tumor by 54%. The decrease in tumor uptake when preinjected or coinjected with Y3-TATE indicates selective binding of SSTR2 for all analogues.
PET/CT Imaging
The PET/CT images for all the 64 Cu and 68 Ga Y3-TATE analogues evaluated in this study (n 5 2) had high contrast for the tumor along with no-target uptake in kidneys and bladder ( Figure 5 and Figure 6 ), except 68 Ga-NOTA-PEG 8 -Y3-TATE (n 5 1), which had low contrast to nontarget uptake. The nontarget uptake in the kidneys and bladder is due to clearance of the PET agents. In comparing the highest SUVs at 4 hours (3.1 6 0.5 and 3.1 6 0.9) ( Table 4) . The Cu-NODAGA-Y3-TATE demonstrated the second highest SUV (3.1 6 1.3) at 1 hour, whereas 64 Cu-labeled NOTA-b-Ala-Y3-TATE (4.0 6 0.6) had the highest, followed by the NODAGA, NOTA-PEG 8 (2.6 6 0.6), and CB-TE2A (2.2 6 0.6) analogues. At 1 hour, the tumor to muscle trend was as follows: 7.2, respectively). 68 Ga-NOTA-PEG 8 -Y3-TATE showed the lowest tumor uptake of all compounds (SUV 5 0.5, n 5 1; see Figure 6 ); however, the 64 Cu agent had higher uptake at 1 and 4 hours (2.6 6 0.6 and 1.9 6 0.4; see Figure 5 ).
Cerenkov Imaging
To demonstrate the multimodal imaging utility of the three 68 Ga-based probes, the HCT116-SSTR2-positive mice were also imaged by Cerenkov imaging in the bioluminescence imaging scanner from 1.5 to 2 hours following PET/CT. In mice imaged with 68 Ga-NODAGA-Y3-TATE, the tumor images showed good contrast with minimal background other than the kidneys (Figure 7 ). Due to the semiquantitative nature of this 2D technique, exact values of uptake could not be calculated, but tumor to muscle ratios were measured through ROI analysis of the planar images generated by the Cerenkov emissions. Following the same trend as PET imaging at 1 hour, 68 Ga-NODAGA-Y3-TATE showed a greater tumor to muscle ratio than 68 Ga-NOTA-b-Ala-Y3-TATE and 68 Ga-NOTA-PEG 8 -Y3-TATE (11 6 4, 4.4 6 7, and 4.4 [n 5 1]). It should be noted that Cerenkov imaging was not attempted on mice injected with 64 Cu-based probes, because the lower beta energy copper emissions produce significantly Cu-CB-TE2A-Y3-TATE 2 hours postinjection (7.2 MBq). PET/CT images were performed with NCr nude mice bearing HCT116-SSTR2 tumors. Images are maximum intensity projections and rotated to achieve the best presentation of the tumor. . PET/CT images were performed with NCr nude mice bearing HCT116-SSTR2 tumors. Images are maximum intensity projections and rotated to achieve the best presentation of the tumor; in the 68 Ga-NOTA-PEG 8 -Y3-TATE image, the tumor is circled due to high activity in the bladder.
less Cerenkov luminescence, and is not optimal for this application.
Discussion
The choice of bifunctional chelator, linker between the chelator and targeting molecule, and radiometal impacts the performance of SSTR-targeted imaging agents. This study focused on the incorporation of NOTA chelators to Y3-TATE, a well-characterized agonist of SSTR2, in comparison with CB-TE2A-Y3-TATE, which we previously showed to have high image contrast for imaging a SSTR2-positive tumor-bearing rat model. 27, 28 The NOTA chelator was selected due to its ability to stably incorporate both 64 Cu and 68
Ga. In addition, NODAGA and p-SCN-Bn-NOTA are commercially available analogues of NOTA that when conjugated provide three carboxylates for N 3 O 3 coordination. [17] [18] [19] [35] [36] [37] The NODAGA chelator was conjugated directly to the N-terminus of Y3-TATE, resulting in an amide bond. NODAGA-Y3-TATE was previously synthesized, labeled with 68 Ga in high specific activity, and evaluated in Rhesus monkey brain sections 38, 39 ; however, to our knowledge, 68 Ga-or 64 Cu-labeled NODAGA-Y3-TATE has not been evaluated in vivo, although NODAGA has been evaluated with the SSTR2 antagonist LM3. 21 In a previously reported study,
64
Cu-labeled NODAGA and CB-TE2A conjugates of the SSTR2 antagonist LM3 were compared, and the NODAGA analogue was deemed superior. One of the goals of this study was to determine if this trend was similar for the widely used SSTR2 agonist Y3-TATE. In addition, we compared these agents to other NOTA-Y3-TATE conjugates and evaluated them in an SSTR2-transfected human cell line, SSTR2-positive HCT116, 29 which can be readily grown in nude mice and is a convenient model for evaluating new radiolabeled SSTR2-targeted agents.
The p-SCN-Bn-NOTA chelate was conjugated using two different linker groups; the linkers are necessary due to the instability of the thiourea bond at the a-amine. The placement of a thiourea directly on the a-amine of a peptide can cause an Edman's degradation, resulting in removal of the terminal amino acid. 40, 41 The movement of the thiourea away from the a-amine can increase the stability of the thiourea when conjugated to a peptide. Banks and Paquette demonstrated that the conjugation through the e-amine of a lysine versus the a-amine was more stable after 10 days at 37uC. 42 Cooper and colleagues demonstrated that p-SCN-Bn-NOTA conjugated through the side chain on lysine forms a stable thiourea bond with no difference in the in vivo stability compared to an amide conjugated chelator. 19 The b-Ala was selected to maintain a probe similar in size to the NODAGA and CB-TE2A analogues, whereas the PEG 8 Cu-NOTA-b-Ala-Y3-TATE having similar, more superior internalization profiles. The in vitro results suggest that the linker length between the chelator and the peptide had an impact on their binding affinity and number of bound receptor sites. The use of the smaller b-Ala linker to maintain a similar linker length between the chelator and peptide when compared to direct conjugation appeared to have little to no effect on the in vitro performance of the radiotracers.
Based on the in vitro results we expected that the in vivo performance of NODAGA-Y3-TATE, NOTA-b-Ala-Y3-TATE, and CB-TE2A-Y3-TATE would be similar, whereas larger NOTA-PEG 8 -Y3-TATE would be less optimal. The tumor uptake and nontargeted organ clearance of Cu-CB-TE2A-Y3-TATE suggest that direct conjugation of Y3-TATE to the a-amine provides a favorable interaction with SSTr2, resulting in increased uptake and retention in the SSTR2 tumor. This is further supported by the performance of the a-conjugated 68 Ga-NODAGA-Y3-TATE, which had superior tumor to muscle/blood ratios in the biodistribution studies and tumor to muscle ratios in both PET/CT and Cerenkov imaging when compared to theb-Ala and -PEG 8 analogues. It should be noted that there were significant differences between the 64 Cu-and 68 Galabeled analogues with respect to the kidney uptake. We hypothesize that this is a result of differences in the overall charge of these chelated metals ( 64 Cu: 21; 68 Ga: neutral). The differences in the kidney uptake should be considered when selecting an imaging agent to minimize the radiation dose delivered to the kidneys. Finally, the choice of the radiometals ( 64 Cu and 68 Ga) with the exception of kidney uptake in the evaluation of the Y3-TATE analogues through biodistribution studies, PET/CT, and Cerenkov imaging did not demonstrate a significant impact on in vivo performance of the NOTA analogues.
Conclusion
Commercially available analogues of NOTA were investigated for radiolabeling with 64 Cu and 68 Ga for SSTR2-targeted PET/CT imaging. The size and method of conjugation had a greater impact on the performance of these SSTR2-targeted PET agents than changes in radiometal, which were determined insignificant. Direct conjugation of a NOTA chelator to the a-amine of Y3-TATE (NODAGA-Y3-TATE) demonstrated superior in vivo performance for 64 Cu-and 68 Ga-labeled analogues compared to the chelator conjugated through a linker. The in vivo performance of 64 Cu-NODAGA-Y3-TATE was comparable to 64 Cu-CB-TE2A-Y3-TATE, one of the gold standard agents that has been investigated in other SSTR2-positive tumor models. Although 64 Cu-CB-TE2A-Y3-TATE was superior to 64 Cu-NODAGA-Y3-TATE in tumor to blood ratios at 4 hours, an advantage of NODAGA-Y3-TATE is that this agent allows for incorporation of both 64 Cu and 68 Ga, incorporates 64 Cu in high radiolabeling yields in a shorter period of time than 64 Cu-CB-TE2A-Y3-TATE, and provides a versatile PET probe for imaging SSTR2-positive tumors.
